Rockwell Medical (RMTI) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RMTI shares.
View RMTI analyst ratings or view top-rated stocks.

1 brokers have issued 1-year price targets for Rockwell Medical's stock. Their RMTI share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 478.9% from the stock's current price.
View analysts price targets for RMTI or view top-rated stocks among Wall Street analysts.

Rockwell Medical's stock was trading at $1.0150 at the start of the year. Since then, RMTI stock has increased by 87.2% and is now trading at $1.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our RMTI earnings forecast.

Rockwell Medical, Inc. (NASDAQ:RMTI) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.06. The business had revenue of $18.08 million for the quarter, compared to the consensus estimate of $18.08 million. Rockwell Medical had a negative net margin of 15.32% and a negative trailing twelve-month return on equity of 88.74%. During the same quarter in the previous year, the company posted ($0.56) EPS.

Shares of Rockwell Medical reverse split on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Rockwell Medical updated its FY 2023 earnings guidance on Sunday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$86.00 million, compared to the consensus revenue estimate of $86.08 million.

6 employees have rated Rockwell Medical Chief Executive Officer Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among the company's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Rockwell Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Richmond Brothers Inc. (3.07%), Renaissance Technologies LLC (2.54%), Stratos Wealth Partners LTD. (1.09%), BlackRock Inc. (0.87%), Geode Capital Management LLC (0.77%) and Perkins Capital Management Inc. (0.58%).
View institutional ownership trends.

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMTI stock can currently be purchased for approximately $1.90.

Rockwell Medical (NASDAQ:RMTI) has a market capitalization of $54.13 million and generates $72.81 million in revenue each year. The company earns $-18,680,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

The company employs 253 workers across the globe.

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The official website for the company is www.rockwellmed.com. The company can be reached via phone at (248) 432-1362, via email at invest@rockwellmed.com, or via fax at 248-960-9119.